New hope for rare, Life-Threatening skin conditions?
NCT ID NCT06474078
First seen Sep 30, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This study tested the drug tofacitinib in 20 adults with Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), rare and severe skin reactions. The main goal was to see how quickly the skin healed completely. Researchers also tracked hospital stays, deaths, side effects, and eye complications. The study was completed and provides early safety and effectiveness data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEVENS-JOHNSON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chang Gung Memorial Hospital
Taoyuan, 333, Taiwan
Conditions
Explore the condition pages connected to this study.